|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 8- ( 3-( R ) -Aminopiperidin-1 -yl ) -7-but-2-ynyl-3-meth- yl-1- ( 4-methyl-quinazolin-2-ylmethyl ) -3,7-dihydro- purine-2,6-dione ( BI1356 ), a highly potent, selec- five, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes 显示文摘 | ECKHARDT M LANGKOPF E MARK M | 2007 | J Med Chem2007，50，26： | 1 |
| 2 | (R)- 8- (3 - amino- pipefidin - 1 - yl) - 7 - hut - 2 - ynyl - 3 - methyl - 1 - (4 - methyl - quinazalin - 2 - ylmethyl ) - 3,7 - dihydro- purine - 2,6 - dione (BI 1356), a novel xanthine- based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase- 4 inhibitors 显示文摘 | THOMAS L ECKHARDTM LANGKOPF E | 2008 | J Pharmaeol Exp Ther2008，325，1： | 1 |
| 3 | First Studies of the Transition Metal-Catalyzed Cycloadditions of Alkenes and Vinylcyclopropanes: Scope and Stereochemistry显示文摘 | Wender P A Husfeld C O Langkopf E | 1998 | J Am Chem Soc1998，120，8： | 1 |
| 4 | 8-(3-(R) Aminopiperidin- l-yl) -7-but-2-ynyl- 3-methyl-t-(4-methylquinazolin 2 ylmethyl)-3,7-dihydropurine-2,6-dione (BI1356), a highly potent, selective, long-acting, and orally bioavailable DPP 4 inhibitor tbr the treatment of type 2 diabetes显示文摘 | Eckhardt M Langkopf E Mark M | 2007 | J Med Chem2007，50，26： | 1 |
| 5 | (R)-8-(3-ami-no-piperidin-1 -yl) -7-but-2 -ynyl-3-methyl-1 - (4-methyl-qu-inazolin-2-ylmethyl) -3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors 显示文摘 | Thomas L Eckhardt M LangkopfE e/al | 2008 | JPharmacolExp Ther2008，325，1： | 1 |
| 6 | 8-(3-(R)-ami-nopiperidin-1 -yl) -7-but-2-ynyl-3-methyl-1 - (4-methyl-qu-inazolin-2-ylmethyl) -3, 7-dihydropxmne-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes显示文摘 | Eckhardt M Langkopf E MarkM | 2007 | JMed Chem2007，50，26： | 1 |
| 7 | (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI 1356),a novel xanthine-based dipeptidyl peptidase 4inhibitor,has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors显示文摘 | THOMAS L ECKHARDT M LANGKOPF E | 2008 | J Pharmacol Exp Ther2008，325，1： | 1 |
| 8 | 8-(3-(R)- aminopiperidin-l-yl )-7-but-2-ynyl-3-methyl-l-( 4-methyl-quin- azolin-2-ylmethyl) -3, 7-dihydropurine-2, 6-dione ( BI 1356) , a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes显示文摘 | ECKHARDTM LANGKOPF E MARK M | 2007 | J Med Chem2007，50，26： | 1 |
| 9 | 8- (3- (R) -Amino-piperidin-l-yl) -7-but-2-ynyl-3-methy-l- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydropurine-2,6-dione (BI1356), a highly potent, selective, long-acting,and orallybioavailable DPP-4 inhibitor for the treatment of type 2diabetes 显示文摘 | Eckhardt M Langkopf E Mark M | 2007 | J Med Chem2007，50，64： | 1 |
| 10 | 8-(3-(R)- Aminopiperidin- 1 - yl) - 7 - but- 2- ynyl- 3- methyl- 1 - (4- methyl- quinazolin - 2 - ylmethyl) - 3, 7 - dihydropurine - 2, 6 - dione (BI 1356), a highly potent, selective, long- acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes 显示文摘 | ECKHARDT M LANGKOPF E MARK M et ol | 2007 | J Med Chem2007，50，26： | 1 |
| 11 | (R)-8- (3 - Amino - piperidin - 1 - yl) - 7 - but - 2 - ynyl - 3 - methyl - 1 - (4 - methyl - quinazolin - 2 - ylmethyl) - 3, 7 - dihydro - purine - 2, 6 -dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase- 4 inhibitors显示文摘 | THOMAS L ECKHARDT M LANGKOPF E | 2008 | J Pharmacol Exp Ther2008，325，1： | 1 |
| 12 | Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses显示文摘 | Zorn U Duensing S Langkopf F | 1997 | Cancer Biother Radio1997，12，： | 1 |
| 13 | (R)-8-(3- amino-piperidin- 1 -yl)-7-but-2-ynyl-3-methyl- 1 -(4-methyl- quinazolin-2-ylm ethyl)- 3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors显示文摘 | Thomas L Eckhardt M Langkopf E | 2008 | J Pharmacol Exp Ther2008，325，1： | 1 |
| 14 | 8-E3-(R) - Aminopiperidin- 1 -yl] -7-but-2-ynyl-3-methyl- 1 - (4-methyl- quinazoln-2-ylmethyl) -3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes 显示文摘 | Eckhardt M Langkopf E Mark M | 2007 | JMed Chem2007，50，26： | 1 |
| 15 | (R) -8- ( 3-Amino-pip- eridin-l-yl )-7-but-2-ynyl-3-methyl-l-( 4-methyl-quinazoli n-2- ylmethyl) -3,7-dihydro-purine-2,6-dione ( BI 1356 ), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipep- tidyl peptidase-4 inhibitors 显示文摘 | Thomas L Eckhardt M Langkopf E | 2008 | J Pharmacol Exp Ther2008，325，1： | 1 |
| 16 | Soluble tumor necrosis factor receptors as prognostic factors in cancer patients 显示文摘 | Atzpodien J | 1994 | Lancet1994，344，： | 1 |
| 17 | (R)-8-(3-amino- piperidin- 1 -yl ) -7 -but-2-ynyl-3 -methyl- 1- (4-methyl-quinazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI 1356),a novel xanthine-based dipeptidyl peptidase 4 inhibitor,has a superior potency and longer duration of action compared with other dipeptidyl peptidase- 4 inhibitors 显示文摘 | Thomas L Eckhardt M Langkopf E | 2008 | J Pharmacol Exp Ther2008，325，1： | 1 |
| 18 | First studies of the transition metal-catalyzed cycloadditions of alkenes and vinylcyclopropanes: Scope and stereo- chemistry显示文摘 | Wender P A Husfeld C O Langkopf E | 1998 | Journal of the American Chemical Society1998，120，8： | 1 |
| 19 | The firstmetal-catalyzed intramolecular cycloadditions of vinylcyclopropanes and alkenes: Scope, stereochemistry, and asymmetric catalysis显示文摘 | Wender P A Husfeld C O Langkopf E | 1998 | Tetrahedron1998，54，25： | 1 |
| 20 | Active Specific Immunotherapy of Renal Cell Carrrcinoma: Cellular and Humoral Immune Responses显示文摘 | Duensing S Langkopf F | 1997 | Cancer Biother Radiopharm1997，12，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员